We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Co-Receptor Tropism Assay Launched for HIV Patients

By Biotechdaily staff writers
Posted on 29 Aug 2007
The human immunodeficiency virus (HIV) diagnostic co-receptor tropism assay has been launched for patients in the United States.

Called Trofile, the assay determines which co-receptor a patient's HIV strain or strains use for viral entry--CCR5, CXCR4, or a combination of CCR5 and CXCR4. More...
The cellular gateways that a particular HIV strain uses to gain entry into a healthy CD4+ cell is known as the patient's tropism.

Trofile amplifies a patient's HIV genome (from his/her blood sample) to make HIV particles specific to that individual patient. The resultant HIV particles are then used to infect CCR5- and CXCR4- expressing cell lines. Once the virus infects the cell and undergoes its single round of replication, a reporter gene expresses its indicator gene (luciferase), giving a visible signal-thus identifying the patient's viral tropism. Viral load must be at least 1,000 copies/ml to determine a patient's viral tropism.

Monogram (San Francisco, CA, USA) announced the commercial introduction of its Trofile assay following the announcement that Pfizer
(New York, NY, USA) received US Food and Drug Administration (FDA) approval of a novel HIV therapy, Selzentry (maraviroc), a CCR% antagonist. Trofile was the test used for patient selection for Selzentry's clinical development program and the two companies are engaged in a collaboration agreement to make Monogram's assay available for patient use globally.

Selzentry has been approved for the combination antiretroviral treatment of adults infected with only CCR5-tropic HIV-1 who have evidence of viral replication and have HIV-1 strains resistant to multiple antiretroviral agents. The FDA-approved label requires that tropism testing to identify patients infected with R5 virus guide the use of Selzentry.

Trofile is a vital new tool that helps physicians make the most informed treatment decisions for their patients living with HIV. Combined with Pfizer's new therapy, this represents a major milestone in the treatment of HIV, said Monogram CEO Bill Young. [The] approval also marks an important landmark in personalized medicine as the healthcare community shifts to treat patients individually by combining powerful diagnostic tools with drug therapies to better predict an individual patient's response.


Related Links:
Monogram
Pfizer

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Steam Sterilizer
Hi Vac II Line
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.